Liraglutide Weight Loss Results
Liraglutide produces ~8% body weight loss on average. SCALE trial data, timelines, and how results compare to semaglutide and tirzepatide.
SCALE avg. loss
8.0% at 56 weeks
Lost >= 5%
63.2% of patients
Lost >= 10%
33.1% of patients
Real-world avg.
5-7% at 12 months
vs. Semaglutide
~47% less effective
SCALE Clinical Trial Data
The SCALE Obesity and Prediabetes trial enrolled 3,731 adults with BMI >= 30 (or >= 27 with comorbidities). At 56 weeks, patients on Saxenda 3.0mg achieved a mean weight loss of 8.0% vs. 2.6% with placebo. Approximately 63.2% lost at least 5% body weight, and 33.1% lost at least 10%.
While these results were considered excellent when Saxenda was approved in 2014, they are now viewed as moderate compared to semaglutide (15%) and tirzepatide (22.5%). Liraglutide remains clinically meaningful but is no longer the most effective option.
Weight Loss Timeline
Weight loss with liraglutide begins during the 5-week titration period and continues steadily for approximately 6-9 months before plateauing. Most patients reach their maximum weight loss by 9-12 months. The rate of loss is more gradual than with semaglutide or tirzepatide, which some patients actually prefer.
Typical trajectory: 2-3% loss by month 2, 5-6% by month 4, 7-8% by month 8, and maximum loss by month 12. Individual variation is significant, with some patients achieving 12-15% loss and others only 3-4%.
Real-World vs. Trial Results
Real-world studies suggest average liraglutide weight loss of 5-7% at 12 months, somewhat lower than the 8% trial average. Contributing factors include lower adherence to daily injections, less structured follow-up, and the availability of more effective alternatives leading some patients to switch before achieving maximum benefit.
Patients who maintain consistent daily dosing and combine medication with lifestyle changes achieve results closest to the clinical trial data.
Comparison to Newer Medications
In the context of 2026, liraglutide's weight loss results are modest compared to alternatives. Semaglutide produces approximately 87% more weight loss (15% vs. 8%), and tirzepatide produces approximately 181% more (22.5% vs. 8%). These differences are clinically significant.
However, liraglutide offers the longest safety track record of any GLP-1 for weight management, with over 10 years of post-market data. For patients prioritizing the most established safety profile, this may outweigh the lower efficacy.
Frequently Asked Questions
How much weight can you lose on Saxenda?
The average is about 8% of body weight over a year. For a 200-pound person, that's approximately 16 pounds. Some patients lose more (12-15%), while others lose less (3-4%). Results depend on adherence and lifestyle factors.
Is liraglutide less effective than semaglutide?
Yes, semaglutide produces approximately 15% weight loss vs. liraglutide's 8% in comparable trials. However, liraglutide has the longest safety record and may be preferred for specific patient populations.
Compare all GLP-1 medication results and providers
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.
Search Providers →Explore all Liraglutide topics
Cost guides, side effect management, dosing information, insurance coverage, and more — all backed by clinical data.